Pharma Sector

Its interest revenue increased by 55% year on year to ₹492 Crore from ₹318 Crore in FY24, while assets under management increased by 34% to ₹10,593 Crore.

With the acquisition of Medica, Manipal facilities now serve 7 million patients yearly across 37 facilities in 19 cities throughout 14 states.

Suresh Narayanan, chairman and managing director of Nestlé India, expressed that this collaboration will empower them to develop a strong retail and distribution infrastructure.

The USFDA also noted the company’s commitment to temporarily halt the production of all drugs made on both dedicated and non-dedicated equipment.

The company's board has decided not to declare an interim dividend for fiscal year 2023-24.

India is the world's largest provider of generic medications, accounting for around 20% of worldwide supply.

Indraprastha Medical maintains two hospitals: one in New Delhi and one in Noida. It is backed by the Delhi government and Apollo Hospitals.

The pharmaceutical stock was offered on public markets in May of last year, at a 20% premium to its issue price of ₹1,080.

Against its annual contracted value of USD50m supplies for Librela, Syngene has supplied USD94m worth of Librela to Zoetis over the past 13 months, which likely implies that Librela supplies to Zoetis will continue to taper off in CY24 and will present a tough base for Syngene going ahead. Syngene shipped just USD2m worth of Librela in Feb’24 vs USD21/13m in Dec’23/Jan’24 respectively.

The complaint alleges Dr Reddy's "improperly restrained competition" and maintained a monopoly for the cancer drug Revlimid.